首页 > 最新文献

中华医学遗传学杂志最新文献

英文 中文
[Phenotypic heterogeneity and management strategies for two brothers with XIAP deficiency syndrome]. [兄弟二人XIAP缺乏症的表型异质性及治疗策略]。
Q4 Medicine Pub Date : 2026-02-10 DOI: 10.3760/cma.j.cn511374-20251023-00623
Hui Hu, Shengnan Wu, Kai Chen, Jingbo Shao, Ting Zhang, Yongmei Xiao

Objective: To summarize the clinical features and management of two brothers affected with X-linked inhibitor of apoptosis protein (XIAP) deficiency.

Methods: This study retrospectively analyzed the clinical presentations, treatment, and follow-up of two brothers with XIAP deficiency diagnosed at Shanghai Children's Hospital in 2020, and summarized similar cases recorded in databases such as PubMed, Wanfang, Chinese Medical Association Journals, and WIP from January 2006 to November 2024. This study was approved by the Medical Ethics Committee of our hospital (Ethics No.: 2025R128-E01).

Results: Patient 1 was the younger brother, who presented at 8 years of age with growth retardation, folliculitis, erythema nodosum, and perineal abscess. Sequencing revealed that he has carried a hemizygous c.566T>C (p.Leu189Pro) variant of the XIAP gene, which was inherited from his mother. He was allergic to infliximab treatment and underwent allogeneic stem cell transplantation (HSCT) in January 2021. During a follow-up of 3 years and 10 months post-transplantation, he showed no gastrointestinal symptoms and had a good outcome. Patient 2 was the elder brother, who presented at 10 years and 6 months of age with growth retardation, rash, and anal fistula. Genetic testing revealed the same variant. He was treated with oral azathioprine but did not have regular follow-ups. At 14-years-and-6-months of age, he had developed severe gastrointestinal infection and hemophagocytic lymphohistiocytosis, which was alleviated after treatment with antibiotics, glucocorticoids, immunoglobulin, and rituximab. He is currently being prepared for HSCT. A total of 13 publications were retrieved, which involved 64 patients from 23 families, with 23 different variants identified. The main clinical manifestations included splenomegaly (34 cases, 53.1%), hemophagocytic lymphohistiocytosis (27 cases, 42.2%), and inflammatory bowel disease or colitis (20 cases, 31.8%). There were significant phenotypic differences among patients from the same family. Thirteen patients (20.3%) underwent HSCT, with a survival rate of 61.5%.

Conclusion: For male children with early onset, poor treatment response, especially those with unexplained splenomegaly and IBD-like symptoms, early genetic testing is recommended. HSCT is a safe and effective treatment for XIAP deficiency. For patients with developmental delay, early onset, and severe IBD phenotype, early transplantation is recommended.

目的:总结兄弟二人X-linked inhibitor of apoptosis protein (XIAP)缺乏症的临床特点及治疗。方法:回顾性分析2020年在上海儿童医院确诊的XIAP缺乏症兄弟2例的临床表现、治疗及随访情况,并总结2006年1月至2024年11月在PubMed、万方、中华医学会期刊、WIP等数据库中记录的类似病例。本研究经我院医学伦理委员会批准(伦理号:: 2025 r128-e01)。结果:患者1为弟弟,8岁时表现为生长迟缓、毛囊炎、结节性红斑、会阴脓肿。测序结果显示,他携带了XIAP基因的半合子C . 566t >C (p.Leu189Pro)变体,该变体遗传自他的母亲。他对英夫利昔单抗治疗过敏,于2021年1月接受了同种异体干细胞移植(HSCT)。在移植后3年10个月的随访中,患者未出现胃肠道症状,预后良好。患者2为哥哥,10岁零6个月时出现生长迟缓、皮疹和肛瘘。基因测试显示了相同的变异。患者口服硫唑嘌呤治疗,但未定期随访。14岁零6个月时出现严重胃肠道感染和噬血细胞性淋巴组织细胞增多症,经抗生素、糖皮质激素、免疫球蛋白和利妥昔单抗治疗后缓解。目前正在为HSCT做准备。共检索了13篇出版物,涉及来自23个家族的64名患者,确定了23种不同的变体。主要临床表现为脾肿大(34例,53.1%)、噬血细胞性淋巴组织细胞增多症(27例,42.2%)、炎性肠病或结肠炎(20例,31.8%)。同一家族患者间存在显著的表型差异。13例患者(20.3%)接受了HSCT,生存率为61.5%。结论:对于起病早、治疗效果差的男性患儿,尤其是有不明原因脾肿大及ibd样症状的患儿,建议早期进行基因检测。造血干细胞移植是一种安全有效的治疗XIAP缺乏症的方法。对于发育迟缓、早发和严重IBD表型的患者,建议早期移植。
{"title":"[Phenotypic heterogeneity and management strategies for two brothers with XIAP deficiency syndrome].","authors":"Hui Hu, Shengnan Wu, Kai Chen, Jingbo Shao, Ting Zhang, Yongmei Xiao","doi":"10.3760/cma.j.cn511374-20251023-00623","DOIUrl":"https://doi.org/10.3760/cma.j.cn511374-20251023-00623","url":null,"abstract":"<p><strong>Objective: </strong>To summarize the clinical features and management of two brothers affected with X-linked inhibitor of apoptosis protein (XIAP) deficiency.</p><p><strong>Methods: </strong>This study retrospectively analyzed the clinical presentations, treatment, and follow-up of two brothers with XIAP deficiency diagnosed at Shanghai Children's Hospital in 2020, and summarized similar cases recorded in databases such as PubMed, Wanfang, Chinese Medical Association Journals, and WIP from January 2006 to November 2024. This study was approved by the Medical Ethics Committee of our hospital (Ethics No.: 2025R128-E01).</p><p><strong>Results: </strong>Patient 1 was the younger brother, who presented at 8 years of age with growth retardation, folliculitis, erythema nodosum, and perineal abscess. Sequencing revealed that he has carried a hemizygous c.566T>C (p.Leu189Pro) variant of the XIAP gene, which was inherited from his mother. He was allergic to infliximab treatment and underwent allogeneic stem cell transplantation (HSCT) in January 2021. During a follow-up of 3 years and 10 months post-transplantation, he showed no gastrointestinal symptoms and had a good outcome. Patient 2 was the elder brother, who presented at 10 years and 6 months of age with growth retardation, rash, and anal fistula. Genetic testing revealed the same variant. He was treated with oral azathioprine but did not have regular follow-ups. At 14-years-and-6-months of age, he had developed severe gastrointestinal infection and hemophagocytic lymphohistiocytosis, which was alleviated after treatment with antibiotics, glucocorticoids, immunoglobulin, and rituximab. He is currently being prepared for HSCT. A total of 13 publications were retrieved, which involved 64 patients from 23 families, with 23 different variants identified. The main clinical manifestations included splenomegaly (34 cases, 53.1%), hemophagocytic lymphohistiocytosis (27 cases, 42.2%), and inflammatory bowel disease or colitis (20 cases, 31.8%). There were significant phenotypic differences among patients from the same family. Thirteen patients (20.3%) underwent HSCT, with a survival rate of 61.5%.</p><p><strong>Conclusion: </strong>For male children with early onset, poor treatment response, especially those with unexplained splenomegaly and IBD-like symptoms, early genetic testing is recommended. HSCT is a safe and effective treatment for XIAP deficiency. For patients with developmental delay, early onset, and severe IBD phenotype, early transplantation is recommended.</p>","PeriodicalId":39319,"journal":{"name":"中华医学遗传学杂志","volume":"43 2","pages":"123-128"},"PeriodicalIF":0.0,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146150811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Molecular mechanism study of fetal nasal bone aplasia due to a frameshift variant of ARSL gene]. 【ARSL基因移码变异导致胎儿鼻骨发育不全的分子机制研究】。
Q4 Medicine Pub Date : 2026-02-10 DOI: 10.3760/cma.j.cn511374-20250715-00433
Yuanzhen Zhu, Ke Wu, Dandan Wu

Objective: To analyze the clinical phenotype and pathogenic mechanism of the ARSL gene variant in a fetus with nasal bone aplasia.

Methods: A 34-year-old pregnant woman who attended Quzhou Maternal and Child Health Care Hospital on January 3, 2023 was selected as the study subject. Whole exome sequencing (WES) was performed on the fetus. Bioinformatics analysis was carried out to identify and prioritize candidate gene variants, followed by Sanger sequencing for familial validation. A mutant plasmid expression vector was constructed and subsequently transfected into HEK293T cells to preliminarily investigate the pathogenetic mechanism of the identified variant. Additionally, a comprehensive review of literature was conducted to systematically summarize the associated clinical phenotypes. This study was approved by the Medical Ethics Committee of Quzhou Maternal and Child Health Care Hospital (Ethics No.: KY-2023-11).

Results: WES revealed that the fetus harbored a c.827del (p.L276Rfs*48) variant of the ARSL gene, for which its mother was heterozygous. Based on the guidelines from the American College of Medical Genetics and Genomics (ACMG), the variant was classified as pathogenic(PVS1+PM2_Supporting). In vitro cellular function studies demonstrated that this variant can result in a substantial decrease in the expression of mutant mRNA, thereby preventing the production of normal ARSL protein. Clinical phenotypes resulting from ARSL gene variants exhibited considerable diversity, with nasal hypoplasia being the most common manifestation.

Conclusion: The c.827del (p.L276Rfs*48) variant of the ARSL gene can lead to degradation of mRNA via the nonsense-mediated mRNA decay pathway, resulting in reduced levels of ARSL protein. The pathogenetic mechanism underlying the ARSL gene variant may be associated with its haploinsufficiency effect.

目的:分析鼻骨发育不全胎儿ARSL基因变异的临床表型及致病机制。方法:选取2013年1月3日在衢州市妇幼保健院就诊的34岁孕妇为研究对象。对胎儿进行全外显子组测序。进行生物信息学分析以识别和优先考虑候选基因变异,然后进行Sanger测序进行家族性验证。构建突变质粒表达载体,转染HEK293T细胞,初步探讨突变的发病机制。此外,对文献进行了全面的回顾,系统地总结了相关的临床表型。本研究经衢州市妇幼保健院医学伦理委员会批准(伦理号::: ky - 2023 - 11)。结果:WES结果显示胎儿携带一个c.827del (p.L276Rfs*48)的ARSL基因变异,母体为杂合子。根据美国医学遗传学与基因组学学会(ACMG)的指南,该变异被归类为致病性(PVS1+ pm2_support)。体外细胞功能研究表明,该变异可导致突变mRNA的表达大幅减少,从而阻止正常ARSL蛋白的产生。由ARSL基因变异引起的临床表型表现出相当大的多样性,鼻发育不全是最常见的表现。结论:ARSL基因c.827del (p.L276Rfs*48)变异可通过无义介导的mRNA衰变途径导致mRNA降解,导致ARSL蛋白水平降低。ARSL基因变异的发病机制可能与其单倍体功能不全效应有关。
{"title":"[Molecular mechanism study of fetal nasal bone aplasia due to a frameshift variant of ARSL gene].","authors":"Yuanzhen Zhu, Ke Wu, Dandan Wu","doi":"10.3760/cma.j.cn511374-20250715-00433","DOIUrl":"https://doi.org/10.3760/cma.j.cn511374-20250715-00433","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the clinical phenotype and pathogenic mechanism of the ARSL gene variant in a fetus with nasal bone aplasia.</p><p><strong>Methods: </strong>A 34-year-old pregnant woman who attended Quzhou Maternal and Child Health Care Hospital on January 3, 2023 was selected as the study subject. Whole exome sequencing (WES) was performed on the fetus. Bioinformatics analysis was carried out to identify and prioritize candidate gene variants, followed by Sanger sequencing for familial validation. A mutant plasmid expression vector was constructed and subsequently transfected into HEK293T cells to preliminarily investigate the pathogenetic mechanism of the identified variant. Additionally, a comprehensive review of literature was conducted to systematically summarize the associated clinical phenotypes. This study was approved by the Medical Ethics Committee of Quzhou Maternal and Child Health Care Hospital (Ethics No.: KY-2023-11).</p><p><strong>Results: </strong>WES revealed that the fetus harbored a c.827del (p.L276Rfs*48) variant of the ARSL gene, for which its mother was heterozygous. Based on the guidelines from the American College of Medical Genetics and Genomics (ACMG), the variant was classified as pathogenic(PVS1+PM2_Supporting). In vitro cellular function studies demonstrated that this variant can result in a substantial decrease in the expression of mutant mRNA, thereby preventing the production of normal ARSL protein. Clinical phenotypes resulting from ARSL gene variants exhibited considerable diversity, with nasal hypoplasia being the most common manifestation.</p><p><strong>Conclusion: </strong>The c.827del (p.L276Rfs*48) variant of the ARSL gene can lead to degradation of mRNA via the nonsense-mediated mRNA decay pathway, resulting in reduced levels of ARSL protein. The pathogenetic mechanism underlying the ARSL gene variant may be associated with its haploinsufficiency effect.</p>","PeriodicalId":39319,"journal":{"name":"中华医学遗传学杂志","volume":"43 2","pages":"102-110"},"PeriodicalIF":0.0,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146150843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Genetic analysis of two cases of submicroscopic chromosomal structural variants leading to abnormal pregnancies]. 【两例亚显微镜下染色体结构变异导致异常妊娠的遗传分析】。
Q4 Medicine Pub Date : 2026-02-10 DOI: 10.3760/cma.j.cn511374-20240709-00414
Chengxiu Xie, Xiong Zhu, Yacong Wang, Qingsong Liu

Objective: To investigate the genetic mechanism for adverse pregnancies due to submicroscopic chromosomal structural variants in two cases, and to provide a precise guidance for preimplantation genetic testing.

Methods: Two families who had visited Chengdu Women's and Children's Central Hospital for reproduction guidance due to recurrent miscarriages, adverse pregnancy history and abnormal genetic testing of the offspring in June and December 2023 were selected as the study subjects. Chromosomal karyotyping and optical genome mapping (OGM) were carried out on peripheral blood samples from the two couples, and preimplantation genetic testing for structural rearrangement (PGT-SR) were performed on the blastocyst trophoblasts. This study was approved by the Medical Ethics Committee of the Hospital (Ethic No.: 2023-23).

Results: No abnormality was found on the G-banded karyotyping analysis for both couples. The OGM results revealed that the female partner of couple 1 had a translocation between 4pter-p16.3 (3.99 Mb) and 11pter-p15.4 (2.66 Mb), whilst no abnormality was found in the male partner. Similarly, the male partner of couple 2 had a translocation between 19q13.43-qter (1.90 Mb) and 22q13.31-qter (3.34 Mb). No abnormality was found in the female partner of couple 2. Neither breakpoints nor the adjacent region had involved an OMIM gene, except the formation of a fusion gene ZIM2-AS1-Z82186.1 (Both genes are non-coding, and the fusion gene was deemed as variant of unknown significance). PGT-SR of 11 blastocysts derived from couple 1 revealed that one embryo was suitable for priority transfer, three embryos were suitable for transfer, one embryo was recommended for genetic counselling, and six embryos were unsuitable for the transfer. For couple 2, six blastocysts were tested, of which only one embryo was deemed suitable for transfer.

Conclusion: When genetic testing of offspring indicates copy number variations such as deletions, duplications or mosaicism, the high-resolution OGM technique can be selected to screen parents for submicroscopic chromosomal structural variations. The result can facilitate accurate assessment for the risk of recurrence in offspring, selection of suitable method for reproduction, and identifying targets for PGT.

目的:探讨2例亚显微染色体结构变异致不良妊娠的遗传机制,为胚胎植入前遗传学检测提供准确指导。方法:选取于2023年6月至12月因反复流产、不良妊娠史及后代基因检测异常而到成都市妇女儿童中心医院接受生殖指导的2户家庭作为研究对象。对两对夫妇外周血进行染色体核型和光学基因组定位(OGM),对胚泡滋养细胞进行着床前结构重排基因检测(PGT-SR)。本研究已获本院医学伦理委员会批准(伦理号:: 2023 - 23)。结果:两对夫妇的g带核型分析均未发现异常。OGM结果显示,夫妇1的女性伴侣在4pter-p16.3 (3.99 Mb)和11pter-p15.4 (2.66 Mb)之间易位,而男性伴侣未发现异常。同样,2号夫妇的男性伴侣在19q13.43-qter (1.90 Mb)和22q13.31-qter (3.34 Mb)之间发生了易位。2号夫妇的女性伴侣未见异常。除了形成一个融合基因ZIM2-AS1-Z82186.1(这两个基因都是非编码的,融合基因被认为是未知意义的变异),断点和邻近区域都没有涉及到OMIM基因。1对夫妇11个囊胚的PGT-SR结果显示,1个胚胎适合优先移植,3个胚胎适合移植,1个胚胎建议进行遗传咨询,6个胚胎不适合移植。对2号夫妇进行了6个囊胚测试,其中只有一个胚胎被认为适合移植。结论:当后代基因检测显示缺失、重复或嵌合等拷贝数变异时,可选择高分辨率OGM技术筛选亲本亚显微染色体结构变异。该结果有助于准确评估子代复发风险,选择合适的繁殖方式,确定PGT的靶点。
{"title":"[Genetic analysis of two cases of submicroscopic chromosomal structural variants leading to abnormal pregnancies].","authors":"Chengxiu Xie, Xiong Zhu, Yacong Wang, Qingsong Liu","doi":"10.3760/cma.j.cn511374-20240709-00414","DOIUrl":"https://doi.org/10.3760/cma.j.cn511374-20240709-00414","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the genetic mechanism for adverse pregnancies due to submicroscopic chromosomal structural variants in two cases, and to provide a precise guidance for preimplantation genetic testing.</p><p><strong>Methods: </strong>Two families who had visited Chengdu Women's and Children's Central Hospital for reproduction guidance due to recurrent miscarriages, adverse pregnancy history and abnormal genetic testing of the offspring in June and December 2023 were selected as the study subjects. Chromosomal karyotyping and optical genome mapping (OGM) were carried out on peripheral blood samples from the two couples, and preimplantation genetic testing for structural rearrangement (PGT-SR) were performed on the blastocyst trophoblasts. This study was approved by the Medical Ethics Committee of the Hospital (Ethic No.: 2023-23).</p><p><strong>Results: </strong>No abnormality was found on the G-banded karyotyping analysis for both couples. The OGM results revealed that the female partner of couple 1 had a translocation between 4pter-p16.3 (3.99 Mb) and 11pter-p15.4 (2.66 Mb), whilst no abnormality was found in the male partner. Similarly, the male partner of couple 2 had a translocation between 19q13.43-qter (1.90 Mb) and 22q13.31-qter (3.34 Mb). No abnormality was found in the female partner of couple 2. Neither breakpoints nor the adjacent region had involved an OMIM gene, except the formation of a fusion gene ZIM2-AS1-Z82186.1 (Both genes are non-coding, and the fusion gene was deemed as variant of unknown significance). PGT-SR of 11 blastocysts derived from couple 1 revealed that one embryo was suitable for priority transfer, three embryos were suitable for transfer, one embryo was recommended for genetic counselling, and six embryos were unsuitable for the transfer. For couple 2, six blastocysts were tested, of which only one embryo was deemed suitable for transfer.</p><p><strong>Conclusion: </strong>When genetic testing of offspring indicates copy number variations such as deletions, duplications or mosaicism, the high-resolution OGM technique can be selected to screen parents for submicroscopic chromosomal structural variations. The result can facilitate accurate assessment for the risk of recurrence in offspring, selection of suitable method for reproduction, and identifying targets for PGT.</p>","PeriodicalId":39319,"journal":{"name":"中华医学遗传学杂志","volume":"43 2","pages":"143-150"},"PeriodicalIF":0.0,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146150876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Association of microRNA gene polymorphisms with risk, clinicopathological characteristics and therapeutical efficacy among Chinese patients with Crohn's disease]. 【中国克罗恩病患者microRNA基因多态性与风险、临床病理特征和治疗效果的关系】。
Q4 Medicine Pub Date : 2026-02-10 DOI: 10.3760/cma.j.cn511374-20250728-00460
Yanlun Zhang, Xiaoxiao Shao, Daopo Lin, Yuan Xu, Guolong Ma, Yi Jiang
<p><strong>Objective: </strong>To assess the association of microribonucleic acid (miRNA) gene polymorphisms with the risk and clinicopathological characteristics of Crohn's disease (CD) and the influence of miRNA gene variants on the response to ustekinumab (UST) treatment among CD patients.</p><p><strong>Methods: </strong>From January 2018 to February 2025, 312 patients diagnosed with CD and 527 gender- and age-matched normal controls were selected as the study subjects at the Department of Gastroenterology of the Second Affiliated Hospital of Wenzhou Medical University. Genotypes of miR-155 (rs767649), miR-21 (rs13137), miR-124 (rs531564) and miR-146a (rs57095329, rs2431697) were determined with multiplex polymerase chain reaction-ligase detection reaction (PCR-LDR) technique. The patients were divided into different subgroups according to the Montreal Classification Criteria for CD. Harvey-Bradshaw index (HBI) and simplified endoscopic score for CD were respectively applied to assess the clinical and endoscopic disease activity of CD. Unconditional logistic regression model was employed to analyze the distribution of miRNA gene polymorphisms between the two groups, as well as their influence on the clinicopathological characteristics of CD patients. Among them, 185 CD patients received first-line UST treatment, with the first sufficient dose of UST (6 mg/kg) administered intravenously. Based on the changes in HBI at week 8, the response of patients to UST treatment was evaluated. Unconditional logistic regression model was employed to analyze the distribution of miRNA gene polymorphisms between clinically responsive group (the decline of HBI ≥ 3 scores compared to week 0) and non-responsive group. All of the P values were adjusted by Bonferroni correction. This study has been approved by the Medical Ethics Committee of the Second Affiliated Hospital of Wenzhou Medical University (Ethics No.: 2025-K-12-01).</p><p><strong>Results: </strong>No significant difference was found in the distribution of miRNA gene polymorphisms between the two groups (all P > 0.05). The variant genotype (TC+CC) of rs2431697 was more common among patients with terminal ileal-type and ileocolic-type CD than those with the colonic-type CD (OR = 4.98, 95%CI: 1.49~16.68, P = 0.009, adjusted P = 0.045). However, the opposite conclusion was drawn for the homozygous variant genotype (TT) of rs13137 and variant genotype (GC+CC) of rs531564 (OR = 0.37, 95%CI: 0.18~0.76, P = 0.007, adjusted P = 0.035; OR = 0.36, 95%CI: 0.18~0.73, P = 0.004, adjusted P = 0.020). Compared to patients with non-stricturing and penetrating CD, the variant genotype (AG+GG) and variant allele (G) of rs57095329 were more common in those with stricturing and penetrating CD (OR = 4.06, 95%CI: 2.46~6.71, P < 0.001, adjusted P < 0.005; OR = 3.12, 95%CI: 2.06~4.73, P < 0.001, adjusted P < 0.005). However, the frequencies of variant genotype (AT+TT) and variant allele (T) of rs13137 were lower among patients
目的:评估微核糖核酸(miRNA)基因多态性与克罗恩病(CD)风险和临床病理特征的关系,以及miRNA基因变异对CD患者对ustekinumab (UST)治疗反应的影响。方法:选择2018年1月至2025年2月在温州医科大学第二附属医院消化内科就诊的312例确诊为CD的患者和527例性别、年龄匹配的正常对照作为研究对象。采用多重聚合酶链反应-连接酶检测反应(PCR-LDR)技术检测miR-155 (rs767649)、miR-21 (rs13137)、miR-124 (rs531564)和miR-146a (rs57095329、rs2431697)的基因型。根据《蒙特利尔CD分类标准》将患者分为不同的亚组,分别采用Harvey-Bradshaw指数(HBI)和简化CD内镜评分评估CD的临床和内镜疾病活动性。采用无条件logistic回归模型分析两组间miRNA基因多态性的分布及其对CD患者临床病理特征的影响。其中185例CD患者接受一线UST治疗,首足剂量(6 mg/kg)静脉给药。根据第8周HBI的变化,评估患者对UST治疗的反应。采用无条件logistic回归模型分析临床反应组(HBI≥3评分较第0周下降)与非反应组miRNA基因多态性的分布。所有P值均采用Bonferroni校正进行调整。本研究已获温州医科大学第二附属医院医学伦理委员会批准(伦理号:No. 523825)。: 2025 - k - 12 - 01)。结果:两组患者miRNA基因多态性分布差异无统计学意义(P < 0.05)。rs2431697变异基因型(TC+CC)在终末回肠型和回肠结肠型CD患者中比结肠型CD患者更常见(OR = 4.98, 95%CI: 1.49~16.68, P = 0.009,调整后P = 0.045)。而rs13137纯合子变异基因型(TT)和rss531564纯合子变异基因型(GC+CC)的结果则相反(OR = 0.37, 95%CI: 0.18~0.76, P = 0.007,调整后P = 0.035; OR = 0.36, 95%CI: 0.18~0.73, P = 0.004,调整后P = 0.020)。与非狭窄性穿透性CD患者相比,狭窄性穿透性CD患者rs57095329变异基因型(AG+GG)和变异等位基因(G)更常见(OR = 4.06, 95%CI: 2.46~6.71, P < 0.001,调整后P < 0.005; OR = 3.12, 95%CI: 2.06~4.73, P < 0.001,调整后P < 0.005)。然而,狭窄性和穿透性CD患者rs13137变异基因型(AT+TT)和变异等位基因(T)的频率低于非狭窄性CD患者(OR = 0.25, 95%CI: 0.15~0.41, P < 0.001,调整后P < 0.005; OR = 0.45, 95%CI: 0.33~0.63, P < 0.001,调整后P < 0.005)。rs57095329变异基因型(AG+GG)和变异等位基因(G)在中度至重度内镜活动患者中比轻度内镜活动患者更常见(OR = 2.01, 95%CI: 1.19~3.42, P = 0.009,调整后P = 0.045; OR = 2.04, 95%CI: 1.28~3.25, P = 0.003,调整后P = 0.015)。第8周临床缓解117例,无缓解68例。与临床无应答组比较,临床应答组rs2431697变异基因型(TC+CC)和变异等位基因(C)更常见(OR = 3.86, 95%CI: 1.80~8.32, P = 0.001,调整后P = 0.005; OR = 2.60, 95%CI: 1.34~5.06, P = 0.005,调整后P = 0.025)。而rs767649变异基因型(TA+AA)在临床反应组的发生率低于无反应组(OR = 0.40, 95%CI: 0.21~0.74, P = 0.004,调整后P = 0.020)。临床反应组与无反应组比较rs13137的变异基因型(AT+TT)和变异等位基因(T)得到相同结论(OR = 0.30, 95%CI: 0.14~0.63, P = 0.002,调整后P = 0.010; OR = 0.54, 95%CI: 0.35~0.82, P = 0.005,调整后P = 0.025)。结论:mirna的遗传多态性与发生CD的风险无关。miR-146a (rs57095329)变体可能增加CD的内镜活动和狭窄或渗透的风险。然而,miR-146a (rs2431697)变体可能会增加回肠受损伤的风险。miR-21 (rs13137)变异体可能降低回肠受损伤的风险以及狭窄或渗透的风险。miR-124 (rs531564)变体可能降低回肠受损伤的风险。在接受UST治疗的患者中,miR-146a (rs2431697)变异可能在第8周增加临床反应。 然而,miR-155 (rs767649)和miR-21 (rs13137)变体都可能在第8周降低临床反应。
{"title":"[Association of microRNA gene polymorphisms with risk, clinicopathological characteristics and therapeutical efficacy among Chinese patients with Crohn's disease].","authors":"Yanlun Zhang, Xiaoxiao Shao, Daopo Lin, Yuan Xu, Guolong Ma, Yi Jiang","doi":"10.3760/cma.j.cn511374-20250728-00460","DOIUrl":"https://doi.org/10.3760/cma.j.cn511374-20250728-00460","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To assess the association of microribonucleic acid (miRNA) gene polymorphisms with the risk and clinicopathological characteristics of Crohn's disease (CD) and the influence of miRNA gene variants on the response to ustekinumab (UST) treatment among CD patients.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;From January 2018 to February 2025, 312 patients diagnosed with CD and 527 gender- and age-matched normal controls were selected as the study subjects at the Department of Gastroenterology of the Second Affiliated Hospital of Wenzhou Medical University. Genotypes of miR-155 (rs767649), miR-21 (rs13137), miR-124 (rs531564) and miR-146a (rs57095329, rs2431697) were determined with multiplex polymerase chain reaction-ligase detection reaction (PCR-LDR) technique. The patients were divided into different subgroups according to the Montreal Classification Criteria for CD. Harvey-Bradshaw index (HBI) and simplified endoscopic score for CD were respectively applied to assess the clinical and endoscopic disease activity of CD. Unconditional logistic regression model was employed to analyze the distribution of miRNA gene polymorphisms between the two groups, as well as their influence on the clinicopathological characteristics of CD patients. Among them, 185 CD patients received first-line UST treatment, with the first sufficient dose of UST (6 mg/kg) administered intravenously. Based on the changes in HBI at week 8, the response of patients to UST treatment was evaluated. Unconditional logistic regression model was employed to analyze the distribution of miRNA gene polymorphisms between clinically responsive group (the decline of HBI ≥ 3 scores compared to week 0) and non-responsive group. All of the P values were adjusted by Bonferroni correction. This study has been approved by the Medical Ethics Committee of the Second Affiliated Hospital of Wenzhou Medical University (Ethics No.: 2025-K-12-01).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;No significant difference was found in the distribution of miRNA gene polymorphisms between the two groups (all P &gt; 0.05). The variant genotype (TC+CC) of rs2431697 was more common among patients with terminal ileal-type and ileocolic-type CD than those with the colonic-type CD (OR = 4.98, 95%CI: 1.49~16.68, P = 0.009, adjusted P = 0.045). However, the opposite conclusion was drawn for the homozygous variant genotype (TT) of rs13137 and variant genotype (GC+CC) of rs531564 (OR = 0.37, 95%CI: 0.18~0.76, P = 0.007, adjusted P = 0.035; OR = 0.36, 95%CI: 0.18~0.73, P = 0.004, adjusted P = 0.020). Compared to patients with non-stricturing and penetrating CD, the variant genotype (AG+GG) and variant allele (G) of rs57095329 were more common in those with stricturing and penetrating CD (OR = 4.06, 95%CI: 2.46~6.71, P &lt; 0.001, adjusted P &lt; 0.005; OR = 3.12, 95%CI: 2.06~4.73, P &lt; 0.001, adjusted P &lt; 0.005). However, the frequencies of variant genotype (AT+TT) and variant allele (T) of rs13137 were lower among patients","PeriodicalId":39319,"journal":{"name":"中华医学遗传学杂志","volume":"43 2","pages":"111-122"},"PeriodicalIF":0.0,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146150820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical efficacy analysis of seven pediatric patients with Acute myeloid leukemia and the t(16;21)(p11;q22) FUS::ERG fusion gene]. [7例小儿急性髓性白血病患者与t(16;21)(p11;q22) FUS::ERG融合基因的临床疗效分析]。
Q4 Medicine Pub Date : 2026-02-10 DOI: 10.3760/cma.j.cn511374-20251020-00612
Lihuan Shi, Shan Huang, Xing Xie, Pengkai Fan, Haili Gao, Yanna Mao

Objective: To analyze the clinical characteristics, treatment, and prognosis of seven pediatric patients with Acute myeloid leukemia (AML) positive for the t(16;21)(p11;q22) FUS::ERG fusion gene.

Methods: A retrospective analysis was carried out on the clinical data, treatment, and prognosis of seven AML patients with t(16;21)(p11;q22) FUS::ERG fusion gene admitted to Henan Children's Hospital between June 2015 and November 2024. Relevant literature was also reviewed. This study was approved by the Medical Ethics Committee of the Hospital (Ethics No.: 2024-102-001).

Results: Among 297 pediatric patients with AML, 7 cases (2.36%) were positive for the t(16;21)(p11;q22) FUS::ERG fusion gene, including 3 males and 4 females, with a median age of 11 years (range: 3 ~ 12 years). According to the FAB classification, these included 1 case of M2, 3 cases of M5, and 3 cases of AML-not otherwise specified (non-M3). All 7 patients were found to harbor the t(16;21)(p11;q22) translocation, with 3 cases showing additional chromosomal abnormalities. Immunophenotyping revealed universal expression of CD13, CD33, CD34, and CD117, with partial expression of CD56, CD4, CD64, CD123, CD15, CD38, CD11b, HLA-DR, cMPO, and CD16. One patient achieved complete remission (CR) after the first course of DAE (cytarabine + daunorubicin + etoposide) induction chemotherapy but relapsed and discontinued the treatment. Six patients received DAH (cytarabine + daunorubicin + homoharringtonine) induction therapy, of whom 2 achieved CR after two courses and underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT), resulting in an overall CR rate of 42.86%. Five children did not receive allo-HSCT and had a median overall survival of 9 months (range: 6 ~ 18 months). Two children who underwent transplantation achieved bone marrow morphological and molecular biological relapse at 6 and 9 months post-transplantation, respectively. After receiving combined chemotherapy and donor lymphocyte infusion, one child failed to achieve remission and died at 22 months post-transplantation, while the other has been followed up to date with positive fusion gene status. Their overall survival was 25 months and 30 months, respectively.

Conclusion: The t(16;21)(p11;q22) FUS::ERG fusion gene is rare in pediatric AML and associated with poor prognosis. Allo-HSCT may mitigate the adverse prognostic impact of the FUS::ERG fusion gene and contribute to prolonged survival.

目的:分析7例t(16;21)(p11;q22) FUS::ERG融合基因阳性的小儿急性髓性白血病(AML)的临床特点、治疗及预后。方法:回顾性分析2015年6月至2024年11月河南省儿童医院收治的7例t(16;21)(p11;q22) FUS::ERG融合基因AML患者的临床资料、治疗及预后。并对相关文献进行了综述。本研究已获本院医学伦理委员会批准(伦理号:: 2024-102-001)。结果:297例小儿AML患者中,t(16;21)(p11;q22) FUS::ERG融合基因阳性7例(2.36%),其中男3例,女4例,中位年龄11岁(范围3 ~ 12岁)。根据FAB分类,包括1例M2, 3例M5, 3例aml -未另行说明(非m3)。7例患者均发现t(16;21)(p11;q22)易位,其中3例出现附加染色体异常。免疫表型分析显示CD13、CD33、CD34和CD117普遍表达,CD56、CD4、CD64、CD123、CD15、CD38、CD11b、HLA-DR、cMPO和CD16部分表达。1例患者在首个疗程的DAE(阿糖胞苷+柔红霉素+依托泊苷)诱导化疗后达到完全缓解(CR),但复发并停止治疗。6例患者接受了DAH(阿糖胞苷+柔红霉素+高杉酸酯碱)诱导治疗,其中2例患者在2个疗程后达到CR,并行同种异体造血干细胞移植(alloo - hsct),总CR率为42.86%。5名儿童未接受同种异体造血干细胞移植,中位总生存期为9个月(范围:6 ~ 18个月)。两名接受移植的儿童分别在移植后6个月和9个月出现骨髓形态和分子生物学复发。在接受联合化疗和供体淋巴细胞输注后,一名儿童未能达到缓解并在移植后22个月死亡,而另一名儿童随访至今融合基因状态为阳性。他们的总生存期分别为25个月和30个月。结论:t(16;21)(p11;q22) FUS::ERG融合基因在小儿AML中少见,且与不良预后相关。同种异体造血干细胞移植可以减轻FUS::ERG融合基因对预后的不良影响,并有助于延长生存期。
{"title":"[Clinical efficacy analysis of seven pediatric patients with Acute myeloid leukemia and the t(16;21)(p11;q22) FUS::ERG fusion gene].","authors":"Lihuan Shi, Shan Huang, Xing Xie, Pengkai Fan, Haili Gao, Yanna Mao","doi":"10.3760/cma.j.cn511374-20251020-00612","DOIUrl":"https://doi.org/10.3760/cma.j.cn511374-20251020-00612","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the clinical characteristics, treatment, and prognosis of seven pediatric patients with Acute myeloid leukemia (AML) positive for the t(16;21)(p11;q22) FUS::ERG fusion gene.</p><p><strong>Methods: </strong>A retrospective analysis was carried out on the clinical data, treatment, and prognosis of seven AML patients with t(16;21)(p11;q22) FUS::ERG fusion gene admitted to Henan Children's Hospital between June 2015 and November 2024. Relevant literature was also reviewed. This study was approved by the Medical Ethics Committee of the Hospital (Ethics No.: 2024-102-001).</p><p><strong>Results: </strong>Among 297 pediatric patients with AML, 7 cases (2.36%) were positive for the t(16;21)(p11;q22) FUS::ERG fusion gene, including 3 males and 4 females, with a median age of 11 years (range: 3 ~ 12 years). According to the FAB classification, these included 1 case of M2, 3 cases of M5, and 3 cases of AML-not otherwise specified (non-M3). All 7 patients were found to harbor the t(16;21)(p11;q22) translocation, with 3 cases showing additional chromosomal abnormalities. Immunophenotyping revealed universal expression of CD13, CD33, CD34, and CD117, with partial expression of CD56, CD4, CD64, CD123, CD15, CD38, CD11b, HLA-DR, cMPO, and CD16. One patient achieved complete remission (CR) after the first course of DAE (cytarabine + daunorubicin + etoposide) induction chemotherapy but relapsed and discontinued the treatment. Six patients received DAH (cytarabine + daunorubicin + homoharringtonine) induction therapy, of whom 2 achieved CR after two courses and underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT), resulting in an overall CR rate of 42.86%. Five children did not receive allo-HSCT and had a median overall survival of 9 months (range: 6 ~ 18 months). Two children who underwent transplantation achieved bone marrow morphological and molecular biological relapse at 6 and 9 months post-transplantation, respectively. After receiving combined chemotherapy and donor lymphocyte infusion, one child failed to achieve remission and died at 22 months post-transplantation, while the other has been followed up to date with positive fusion gene status. Their overall survival was 25 months and 30 months, respectively.</p><p><strong>Conclusion: </strong>The t(16;21)(p11;q22) FUS::ERG fusion gene is rare in pediatric AML and associated with poor prognosis. Allo-HSCT may mitigate the adverse prognostic impact of the FUS::ERG fusion gene and contribute to prolonged survival.</p>","PeriodicalId":39319,"journal":{"name":"中华医学遗传学杂志","volume":"43 2","pages":"90-95"},"PeriodicalIF":0.0,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146150818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Prenatal phenotype and genetic analysis of two fetuses with Osteocraniostenosis due to variants of FAM111A gene]. [2例FAM111A基因变异致颅骨狭窄胎儿的产前表型和遗传分析]。
Q4 Medicine Pub Date : 2026-02-10 DOI: 10.3760/cma.j.cn511374-20251030-00635
Lingyi Zhang, Zhigang Zhang, Xingguang Wang, Yanyan Li

Objective: To investigate the prenatal manifestation and genetic basis for two fetuses suspected for Osteocraniostenosis (OCS).

Methods: Two fetuses undergoing invasive prenatal diagnosis at Cangzhou People's Hospital in April and August 2021 for short long bones and abnormal skull morphology were selected as the study subjects. Clinical data were collected and analyzed. Genomic DNA was extracted from amniotic fluid and peripheral blood samples of the two couples. Candidate variants were validated by Sanger sequencing. Literature was retrieved from CNKI, Wanfang Data Knowledge Service Platform and PubMed using keywords including "FAM111A gene", "gracile bone dysplasia", "FAM111A" and "osteocraniostenosis" from January 1, 2000 to June 30, 2025. This study was approved by the Medical Ethics Committee of the hospital (Ethics No.: K2020-049).

Results: Fetus 1 was found to have short limbs, abnormal skull morphology and shallow cerebral sulci. Fetus 2 showed short limbs, irregular skull halo, prominent forehead and bilateral frontal narrowing. Trio-WES revealed that fetus 1 has carried a heterozygous missense variant c.1582G>C (p.Asp528His) in exon 4 of the FAM111A gene, which was unreported previously. Fetus 2 has harbored a heterozygous in-frame deletion c.1020_1022delTTC (p.Ser343del) in exon 6 of the FAM111A gene, which has been recorded as likely pathogenic by the ClinVar and HGMD databases. Sanger sequencing confirmed that the parents of both fetuses were wild-type for the variant sites. A total of 9 previously reported patients with FAM111A-related gracile bone dysplasia/OCS from 4 publications were retrieved. The main clinical features included intrauterine growth restriction, hypomineralized skull, gracile long bones with narrow medullary cavities and characteristic facial anomalies, which were in large in keeping with the prenatal features of the two fetuses.

Conclusion: Both fetuses were diagnosed with FAM111A-related OCS based on the characteristic prenatal findings and identification of the FAM111A variants. Above finding expanded the phenotypic spectrum of FAM111A-associated disorders and provided clues for the prenatal diagnosis and genetic counseling.

目的:探讨两例疑似骨颅狭窄(OCS)胎儿的产前表现及遗传基础。方法:选择2021年4月和8月在沧州市人民医院行有创产前诊断的2例长骨短、颅骨形态异常胎儿作为研究对象。收集临床资料并进行分析。从两对夫妇的羊水和外周血样本中提取基因组DNA。候选变异通过Sanger测序进行验证。文献检索于2000年1月1日至2025年6月30日,检索词为“FAM111A基因”、“细骨发育不良”、“FAM111A”、“骨颅狭窄”,检索自中国知网、万方数据知识服务平台和PubMed。本研究经本院医学伦理委员会批准(伦理号:: k2020 - 049)。结果:1号胎儿四肢短小,颅骨形态异常,脑沟浅。胎儿2四肢短小,颅晕不规则,前额突出,双侧额部狭窄。Trio-WES发现胎儿1在FAM111A基因外显子4携带一个杂合错义变异体C . 1582g >c (p.Asp528His),这是以前未报道的。胎儿2在FAM111A基因的第6外显子中存在一帧内杂合缺失c.1020_1022delTTC (p.Ser343del), ClinVar和HGMD数据库已记录为可能致病。桑格测序证实,两个胎儿的父母都是变异位点的野生型。我们从4篇出版物中检索了9例先前报道的与fam111a相关的纤细骨发育不良/OCS患者。主要临床特征为宫内生长受限,颅骨低矿化,长骨纤细,髓腔狭窄,面部特征性异常,与两胎的产前特征大体相符。结论:基于特有的产前检查结果和FAM111A变异的鉴定,两例胎儿均诊断为FAM111A相关OCS。以上发现扩大了fam111a相关疾病的表型谱,为产前诊断和遗传咨询提供了线索。
{"title":"[Prenatal phenotype and genetic analysis of two fetuses with Osteocraniostenosis due to variants of FAM111A gene].","authors":"Lingyi Zhang, Zhigang Zhang, Xingguang Wang, Yanyan Li","doi":"10.3760/cma.j.cn511374-20251030-00635","DOIUrl":"https://doi.org/10.3760/cma.j.cn511374-20251030-00635","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the prenatal manifestation and genetic basis for two fetuses suspected for Osteocraniostenosis (OCS).</p><p><strong>Methods: </strong>Two fetuses undergoing invasive prenatal diagnosis at Cangzhou People's Hospital in April and August 2021 for short long bones and abnormal skull morphology were selected as the study subjects. Clinical data were collected and analyzed. Genomic DNA was extracted from amniotic fluid and peripheral blood samples of the two couples. Candidate variants were validated by Sanger sequencing. Literature was retrieved from CNKI, Wanfang Data Knowledge Service Platform and PubMed using keywords including \"FAM111A gene\", \"gracile bone dysplasia\", \"FAM111A\" and \"osteocraniostenosis\" from January 1, 2000 to June 30, 2025. This study was approved by the Medical Ethics Committee of the hospital (Ethics No.: K2020-049).</p><p><strong>Results: </strong>Fetus 1 was found to have short limbs, abnormal skull morphology and shallow cerebral sulci. Fetus 2 showed short limbs, irregular skull halo, prominent forehead and bilateral frontal narrowing. Trio-WES revealed that fetus 1 has carried a heterozygous missense variant c.1582G>C (p.Asp528His) in exon 4 of the FAM111A gene, which was unreported previously. Fetus 2 has harbored a heterozygous in-frame deletion c.1020_1022delTTC (p.Ser343del) in exon 6 of the FAM111A gene, which has been recorded as likely pathogenic by the ClinVar and HGMD databases. Sanger sequencing confirmed that the parents of both fetuses were wild-type for the variant sites. A total of 9 previously reported patients with FAM111A-related gracile bone dysplasia/OCS from 4 publications were retrieved. The main clinical features included intrauterine growth restriction, hypomineralized skull, gracile long bones with narrow medullary cavities and characteristic facial anomalies, which were in large in keeping with the prenatal features of the two fetuses.</p><p><strong>Conclusion: </strong>Both fetuses were diagnosed with FAM111A-related OCS based on the characteristic prenatal findings and identification of the FAM111A variants. Above finding expanded the phenotypic spectrum of FAM111A-associated disorders and provided clues for the prenatal diagnosis and genetic counseling.</p>","PeriodicalId":39319,"journal":{"name":"中华医学遗传学杂志","volume":"43 2","pages":"96-101"},"PeriodicalIF":0.0,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146150797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Genetic analysis and prenatal diagnosis of structural brain abnormalities associated with TUBB gene c.155A>G variant]. [TUBB基因c.155A >g变异相关脑结构异常的遗传分析及产前诊断]。
Q4 Medicine Pub Date : 2026-02-10 DOI: 10.3760/cma.j.cn511374-20250801-00472
Yifan Liu, Wei Song, Xinlian Wang, Yan Ruan, Meng Zhang, Yujiao Chen, Yan Liu, Puqing Zhang, Li Wang, Yousheng Yan

Objective: To explore the genotype-phenotype correlation in a Chinese family with structural brain abnormalities due to variant of the TUBB gene.

Methods: A family undergoing prenatal diagnosis at Beijing Obstetrics and Gynecology Hospital in October 2024 was selected as the study subject. Clinical data were collected. Amniotic fluid sample was subjected to chromosomal copy number variation sequencing (CNV-seq). Trio whole-exome sequencing (Trio-WES) was carried out on the amniotic fluid and parental blood samples, and candidate variant was verified by Sanger sequencing. This study was approved by the Medical Ethics Committee of the hospital (Ethics No.: 2023-KY-076-01).

Results: Both prenatal ultrasound and fetal MRI showed deviation of brain midline, unilateral lateral ventriculomegaly, and bilateral gyral asymmetry. Trio-WES revealed that the fetus has harbored a maternally derived heterozygous missense variant of the TUBB gene [NM_178014.4: c.155A>G (p.N52S)]. Sanger sequencing confirmed that the woman and a previously terminated fetus both harbored the same variant. Both the proband and two fetuses exhibited similar neuroimaging abnormalities including midline deviation and asymmetrical gyri. Based on the guidelines from the American College of Medical Genetics and Genomics (ACMG), the variant was classified as likely pathogenic (PM2_Supporting+PS2_Moderate+PS3).

Conclusion: The heterozygous c.155A>G (p.N52S) variant was the TUBB gene probably underlay the pathogenesis of the structural brain abnormalities in this family. Above findings have expanded the phenotypic spectrum associated with the variant and facilitated the prenatal diagnosis for this family.

目的:探讨TUBB基因变异所致脑结构异常家族的基因型-表型相关性。方法:选择2024年10月在北京妇产科医院产前诊断的1个家庭作为研究对象。收集临床资料。对羊水样本进行染色体拷贝数变异测序(CNV-seq)。对羊水和亲本血液样本进行三重奏全外显子组测序(Trio- wes),并通过Sanger测序对候选变异进行验证。本研究经本院医学伦理委员会批准(伦理号:: 2023 - ky - 076 - 01)。结果:产前超声和胎儿MRI均显示脑中线偏离,单侧侧脑室肿大,双侧脑回不对称。Trio-WES结果显示胎儿携带了母体衍生的TUBB基因杂合错义变体[NM_178014.4: c.155A>G (p.N52S)]。桑格测序证实,这名妇女和之前被终止妊娠的胎儿都携带相同的基因变体。先证者和两个胎儿都表现出类似的神经影像学异常,包括中线偏离和脑回不对称。根据美国医学遗传学和基因组学学院(ACMG)的指南,该变异被归类为可能致病(pm2_support +PS2_Moderate+PS3)。结论:c.155A >g (p.N52S)杂合变异为TUBB基因,可能是该家族脑结构异常发病机制的基础。上述发现扩大了与该变异相关的表型谱,促进了该家族的产前诊断。
{"title":"[Genetic analysis and prenatal diagnosis of structural brain abnormalities associated with TUBB gene c.155A>G variant].","authors":"Yifan Liu, Wei Song, Xinlian Wang, Yan Ruan, Meng Zhang, Yujiao Chen, Yan Liu, Puqing Zhang, Li Wang, Yousheng Yan","doi":"10.3760/cma.j.cn511374-20250801-00472","DOIUrl":"https://doi.org/10.3760/cma.j.cn511374-20250801-00472","url":null,"abstract":"<p><strong>Objective: </strong>To explore the genotype-phenotype correlation in a Chinese family with structural brain abnormalities due to variant of the TUBB gene.</p><p><strong>Methods: </strong>A family undergoing prenatal diagnosis at Beijing Obstetrics and Gynecology Hospital in October 2024 was selected as the study subject. Clinical data were collected. Amniotic fluid sample was subjected to chromosomal copy number variation sequencing (CNV-seq). Trio whole-exome sequencing (Trio-WES) was carried out on the amniotic fluid and parental blood samples, and candidate variant was verified by Sanger sequencing. This study was approved by the Medical Ethics Committee of the hospital (Ethics No.: 2023-KY-076-01).</p><p><strong>Results: </strong>Both prenatal ultrasound and fetal MRI showed deviation of brain midline, unilateral lateral ventriculomegaly, and bilateral gyral asymmetry. Trio-WES revealed that the fetus has harbored a maternally derived heterozygous missense variant of the TUBB gene [NM_178014.4: c.155A>G (p.N52S)]. Sanger sequencing confirmed that the woman and a previously terminated fetus both harbored the same variant. Both the proband and two fetuses exhibited similar neuroimaging abnormalities including midline deviation and asymmetrical gyri. Based on the guidelines from the American College of Medical Genetics and Genomics (ACMG), the variant was classified as likely pathogenic (PM2_Supporting+PS2_Moderate+PS3).</p><p><strong>Conclusion: </strong>The heterozygous c.155A>G (p.N52S) variant was the TUBB gene probably underlay the pathogenesis of the structural brain abnormalities in this family. Above findings have expanded the phenotypic spectrum associated with the variant and facilitated the prenatal diagnosis for this family.</p>","PeriodicalId":39319,"journal":{"name":"中华医学遗传学杂志","volume":"43 2","pages":"136-142"},"PeriodicalIF":0.0,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146150816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Guidelines for the diagnosis, treatment, and management of Citrin deficiency (2026 Edition)]. [柑桔素缺乏症的诊断、治疗和管理指南(2026版)]。
Q4 Medicine Pub Date : 2026-02-10 DOI: 10.3760/cma.j.cn511374-20251121-00678
Division Of Biochemistry And Metabolism Medical Genetics Branch Chinese Medical Association, Division Of Genetics And Metabolism Child Diseases And Health Care Branch Chinese Association For Maternal And Child Health Care, Xinwen Huang

Citrin deficiency is an inherited metabolic disease that primarily affects the liver, growth and development, and can even lead to death. To deepen the understanding of this disease and improve the diagnostic and therapeutic levels as well as the standardized management of doctors in the relevant fields in China, this "Guidelines for the diagnosis, treatment, and management of Citrin deficiency" have been formulated. This guideline can provide opinions over eight clinical issues related to the diagnosis, treatment, and management of Citrin deficiency based on the currently available clinical evidence.

柠檬酸缺乏症是一种遗传性代谢疾病,主要影响肝脏、生长发育,甚至可能导致死亡。为加深对本病的认识,提高中国相关领域医生的诊疗水平和规范化管理,特制定《柑橘素缺乏症诊疗管理指南》。本指南可以根据现有的临床证据,就柑橘素缺乏症的诊断、治疗和管理等八个临床问题提供意见。
{"title":"[Guidelines for the diagnosis, treatment, and management of Citrin deficiency (2026 Edition)].","authors":"Division Of Biochemistry And Metabolism Medical Genetics Branch Chinese Medical Association, Division Of Genetics And Metabolism Child Diseases And Health Care Branch Chinese Association For Maternal And Child Health Care, Xinwen Huang","doi":"10.3760/cma.j.cn511374-20251121-00678","DOIUrl":"https://doi.org/10.3760/cma.j.cn511374-20251121-00678","url":null,"abstract":"<p><p>Citrin deficiency is an inherited metabolic disease that primarily affects the liver, growth and development, and can even lead to death. To deepen the understanding of this disease and improve the diagnostic and therapeutic levels as well as the standardized management of doctors in the relevant fields in China, this \"Guidelines for the diagnosis, treatment, and management of Citrin deficiency\" have been formulated. This guideline can provide opinions over eight clinical issues related to the diagnosis, treatment, and management of Citrin deficiency based on the currently available clinical evidence.</p>","PeriodicalId":39319,"journal":{"name":"中华医学遗传学杂志","volume":"43 2","pages":"81-89"},"PeriodicalIF":0.0,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146150874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Analysis of a three-generation Chinese pedigree affected with Hereditary spastic paraplegia type 3A due to variant of ATL1 gene]. 【中国一家三代ATL1基因变异致遗传性痉挛性截瘫3A型家系分析】。
Q4 Medicine Pub Date : 2026-02-10 DOI: 10.3760/cma.j.cn511374-20251021-00619
Zhenhua Gong, Fengjuan He, Changshui Chen, Yu An

Objective: To explore the genetic basis for a Chinese pedigree affected with Hereditary spastic paraplegia type 3A (SPG3A) and the genotype-phenotype correlation.

Methods: A three-generation pedigree presented at Huantai Maternal and Child Health Care Hospital in March 2021 was selected as the study subject. Whole-exome sequencing (WES) and pedigree analysis was carried out. Candidate variant was validated by Sanger sequencing of the members from the pedigree. Haplotype analysis was used to trace the origin of the variant, and pathogenicity was rated based on the guidelines from the American College of Medical Genetics and Genomics (ACMG). This study was approved by the Medical Ethics Committee of the Hospital (Ethics No.: 2025-12).

Results: A c.1024C>T (p.Pro342Ser) variant of the ATL1 was identified in the four affected members, including the proband, but none of the three unaffected relatives. Haplotype analysis suggested that the variant was derived from the proband's mother and has co-segregated with the disease phenotype. Based on the guidelines of the ACMG, it was classified as likely pathogenic.

Conclusion: The ATL1 c.1024C>T (p.Pro342Ser) variant probably underlay the pathogenesis in this pedigree. Above finding has enriched the mutational spectrum of ATL1 and phenotypic spectrum of SPG3A in the Chinese population, and enabled genetic counseling for this pedigree.

目的:探讨中国遗传性痉挛性截瘫3A型(SPG3A)家系的遗传基础及基因型与表型的相关性。方法:选择2021年3月在环台妇幼保健院就诊的一只三代家系作为研究对象。全外显子组测序(WES)和家系分析。候选变异通过家谱成员的Sanger测序进行验证。单倍型分析用于追踪变异的起源,并根据美国医学遗传学和基因组学学院(ACMG)的指南对致病性进行评级。本研究已获本院医学伦理委员会批准(伦理号:: 2025 - 12)。结果:在包括先证者在内的4名受影响成员中发现了c.1024C>T (p.Pro342Ser) ATL1变异,但在3名未受影响的亲属中未发现。单倍型分析表明,该变异来源于先证者的母亲,并与疾病表型共分离。根据ACMG的指导方针,它被归类为可能致病。结论:at1c . 1024c >T (p.p pro342ser)变异可能是该家系发病机制的基础。以上发现丰富了中国人群中ATL1突变谱和SPG3A表型谱,为该家系的遗传咨询提供了可能。
{"title":"[Analysis of a three-generation Chinese pedigree affected with Hereditary spastic paraplegia type 3A due to variant of ATL1 gene].","authors":"Zhenhua Gong, Fengjuan He, Changshui Chen, Yu An","doi":"10.3760/cma.j.cn511374-20251021-00619","DOIUrl":"https://doi.org/10.3760/cma.j.cn511374-20251021-00619","url":null,"abstract":"<p><strong>Objective: </strong>To explore the genetic basis for a Chinese pedigree affected with Hereditary spastic paraplegia type 3A (SPG3A) and the genotype-phenotype correlation.</p><p><strong>Methods: </strong>A three-generation pedigree presented at Huantai Maternal and Child Health Care Hospital in March 2021 was selected as the study subject. Whole-exome sequencing (WES) and pedigree analysis was carried out. Candidate variant was validated by Sanger sequencing of the members from the pedigree. Haplotype analysis was used to trace the origin of the variant, and pathogenicity was rated based on the guidelines from the American College of Medical Genetics and Genomics (ACMG). This study was approved by the Medical Ethics Committee of the Hospital (Ethics No.: 2025-12).</p><p><strong>Results: </strong>A c.1024C>T (p.Pro342Ser) variant of the ATL1 was identified in the four affected members, including the proband, but none of the three unaffected relatives. Haplotype analysis suggested that the variant was derived from the proband's mother and has co-segregated with the disease phenotype. Based on the guidelines of the ACMG, it was classified as likely pathogenic.</p><p><strong>Conclusion: </strong>The ATL1 c.1024C>T (p.Pro342Ser) variant probably underlay the pathogenesis in this pedigree. Above finding has enriched the mutational spectrum of ATL1 and phenotypic spectrum of SPG3A in the Chinese population, and enabled genetic counseling for this pedigree.</p>","PeriodicalId":39319,"journal":{"name":"中华医学遗传学杂志","volume":"43 2","pages":"129-135"},"PeriodicalIF":0.0,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146150886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Research progress on the molecular genetic mechanism of Parkinson's disease]. 【帕金森病分子遗传机制研究进展】。
Q4 Medicine Pub Date : 2026-02-10 DOI: 10.3760/cma.j.cn511374-20251021-00617
Wei Quan

The pathogenesis of Parkinson's disease is closely related to genetic factors. This article has systematically reviewed the research progress of molecular genetic mechanism on Parkinson's disease by focusing on the role of six high-penetrance pathogenic genes (SNCA, LRRK2, PRKN, PINK1, PARK7, and VPS35) and some risk genes (such as GBA1). These genetic variants eventually converge in three core pathogenic biological pathways, including lysosomal-autophagy pathway disorder, mitochondrial quality control disorder and α-synuclein metabolic abnormality. In-depth understanding of these molecular mechanisms is of great significance for the development of targeted therapy and realization of precision medicine for this disease.

帕金森病的发病机制与遗传因素密切相关。本文从SNCA、LRRK2、PRKN、PINK1、PARK7、VPS35等6个高外显率致病基因和GBA1等危险基因的作用出发,系统综述了帕金森病分子遗传机制的研究进展。这些遗传变异最终汇聚为溶酶体自噬途径紊乱、线粒体质量控制紊乱和α-突触核蛋白代谢异常这三个核心致病生物学途径。深入了解这些分子机制对于开展针对该疾病的靶向治疗和实现精准医疗具有重要意义。
{"title":"[Research progress on the molecular genetic mechanism of Parkinson's disease].","authors":"Wei Quan","doi":"10.3760/cma.j.cn511374-20251021-00617","DOIUrl":"https://doi.org/10.3760/cma.j.cn511374-20251021-00617","url":null,"abstract":"<p><p>The pathogenesis of Parkinson's disease is closely related to genetic factors. This article has systematically reviewed the research progress of molecular genetic mechanism on Parkinson's disease by focusing on the role of six high-penetrance pathogenic genes (SNCA, LRRK2, PRKN, PINK1, PARK7, and VPS35) and some risk genes (such as GBA1). These genetic variants eventually converge in three core pathogenic biological pathways, including lysosomal-autophagy pathway disorder, mitochondrial quality control disorder and α-synuclein metabolic abnormality. In-depth understanding of these molecular mechanisms is of great significance for the development of targeted therapy and realization of precision medicine for this disease.</p>","PeriodicalId":39319,"journal":{"name":"中华医学遗传学杂志","volume":"43 2","pages":"151-157"},"PeriodicalIF":0.0,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146150856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
中华医学遗传学杂志
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1